Male Hypogonadism Treatment Algorithm: A Line-by-Line Therapy Guide

What this algorithm is and is not

This page maps the sequence clinicians generally use once male hypogonadism (also called testosterone deficiency syndrome, distinct from anabolic-androgenic steroid misuse and distinct from female hypogonadism) has been diagnosed. It is not a substitute for an individualized evaluation, and it does not provide a specific dose for any one patient. Where the source literature behind commonly repeated numbers could not be independently verified for this draft, that is stated explicitly rather than presented as a precise fact.

A confirmed diagnosis requires two separate morning, fasting total testosterone values below approximately 300 ng/dL together with at least one compatible symptom or sign: reduced libido, erectile dysfunction, decreased spontaneous erections, gynecomastia, reduced body hair, small or soft testes, infertility, or low bone mineral density. This threshold and testing approach reflects the general framework used in the Endocrine Society's clinical practice guideline on testosterone therapy in men with hypogonadism and is echoed in more recent European Association of Urology guidance on male hypogonadism (EAU 2025 update). Exogenous testosterone therapy suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis, which is why fertility intentions must be established before any formulation is chosen, not after.

Step zero: confirming the diagnosis and classifying it

Testosterone follows a circadian rhythm, peaking in the early morning and declining over the day, which is why blood should be drawn before roughly 10:00 AM. Recent food intake, acute illness, and some medications can also transiently lower measured testosterone, which is part of why guidelines require two separate measurements rather than one.

Once low testosterone is confirmed, classification matters. Primary hypogonadism (testicular failure) typically shows high LH and FSH. Secondary hypogonadism (hypothalamic-pituitary dysfunction) shows low or inappropriately normal gonadotropins. This distinction affects both prognosis and which second-line agents can work at all: fertility-sparing agents that act by raising endogenous gonadotropin signaling (clomiphene, hCG) depend on the testes being able to respond to that signal, so they are generally not effective in primary hypogonadism where the testicular tissue itself has failed.

Measuring LH, FSH, and prolactin in men with confirmed low testosterone helps identify treatable secondary causes such as prolactin-secreting pituitary tumors, iron overload, or chronic opioid use. A markedly elevated prolactin level or unexplained gonadotropin suppression should prompt pituitary imaging and endocrinology referral rather than empiric treatment.

First line: lifestyle optimization and reversible-cause correction

Before prescribing any hormone or hormone-adjacent medication, clinicians look for what can be fixed without one. Obesity-related testosterone suppression is often described as "functional hypogonadism": the hypothalamic-pituitary-gonadal axis is suppressed by excess adipose tissue and its metabolic effects rather than by structural gland damage, and it can improve with weight loss alone. The exact magnitude of testosterone recovery with a given amount of weight loss varies across studies and populations; readers should treat any single precise number (for example, a specific milligram-per-deciliter increase per percent body weight lost) as an approximation pending confirmation against the primary trial, not a guarantee for an individual patient.

Medication review is equally important. Chronic opioid use is a well-documented cause of suppressed testosterone through reduced GnRH pulsatility, and stopping or reducing opioids, where clinically appropriate, can partially or fully reverse this. Glucocorticoids, 5-alpha reductase inhibitors, and spironolactone also warrant review. Untreated obstructive sleep apnea is another reversible contributor, and treating it with CPAP may partially restore nocturnal testosterone secretion, though sleep apnea treatment alone does not reliably normalize testosterone in every patient.

If testosterone normalizes after these interventions, further pharmacotherapy is generally unnecessary. A recheck at around 3 months is a reasonable interval to assess response.

Second line: fertility-sparing pharmacotherapy

For men who want to preserve or restore fertility, agents that stimulate the patient's own testosterone production are preferred over exogenous testosterone, which shuts fertility down.

Clomiphene citrate is an estrogen receptor antagonist at the hypothalamus and pituitary that increases GnRH pulse frequency and downstream LH/FSH secretion, raising endogenous testosterone while generally preserving sperm parameters. It is FDA-approved only for female ovulatory dysfunction; its use in men is off-label, though it is commonly prescribed by urologists and reproductive endocrinologists and has a substantial observational and small-trial evidence base.

Human chorionic gonadotropin (hCG) acts as an LH analog, directly stimulating Leydig cell testosterone production while maintaining the high intratesticular testosterone concentration that spermatogenesis depends on. It is typically given as a subcutaneous injection several times weekly.

Enclomiphene, the trans-isomer of clomiphene, has been studied in phase 3 trials as a potentially cleaner alternative with fewer estrogenic effects, but its regulatory status should be checked at the time of prescribing rather than assumed to be FDA-approved.

This line of therapy makes physiologic sense mainly in secondary hypogonadism, where the testes retain the capacity to respond to increased gonadotropin signal. It is a poor fit for primary testicular failure.

Third line: testosterone replacement therapy

When lifestyle measures have not resolved the deficiency, fertility is not an active concern, and organic hypogonadism is confirmed, TRT becomes the standard approach. Several formulations exist, and the choice depends on patient preference, cost, insurance coverage, and pharmacokinetic tradeoffs.

Topical gels (1% or 1.62% testosterone) are among the most commonly prescribed formulations in the United States. Applied daily, they reach relatively steady-state levels over several weeks. Transference to household contacts, particularly women and children, is a real risk and requires counseling on application site and hand washing.

Intramuscular injections of testosterone cypionate or enanthate are typically the least expensive option but produce peak-and-trough fluctuations, with supraphysiologic levels shortly after injection and lower levels before the next dose. More frequent, lower-dose injections can smooth this curve.

Testosterone undecanoate (brand name Aveed) is a long-acting intramuscular option. Its FDA label carries a boxed warning and requires a Risk Evaluation and Mitigation Strategy (REMS) because of reports of pulmonary oil microembolism and anaphylaxis; each injection must be given in a healthcare setting with a post-injection observation period (FDA label).

Nasal testosterone gel avoids transference risk and is dosed multiple times daily; its pulsatile delivery pattern may partially preserve gonadotropin secretion compared with continuous formulations, though this has not been shown to translate into a fertility benefit.

Subcutaneous pellets offer the longest dosing interval among available options but require a minor in-office procedure and carry a meaningful extrusion risk.

Absolute contraindications to TRT

Widely recognized contraindications include a near-term desire for fertility, active or suspected breast or prostate cancer, a baseline hematocrit above roughly 50%, untreated severe obstructive sleep apnea, uncontrolled heart failure, and an unevaluated prostate nodule or markedly elevated PSA. Any of these findings should prompt evaluation before TRT is started, not after.

Monitoring on testosterone therapy

Total testosterone is generally rechecked 3 to 6 months after starting therapy, then roughly annually, with a treatment goal in the mid-normal range.

Hematocrit is the most clinically significant safety parameter because testosterone stimulates red blood cell production. The largest cardiovascular safety trial of TRT to date, TRAVERSE, followed several thousand men and did not find an increased rate of major cardiovascular events with testosterone gel compared with placebo over roughly 2.5 to 3 years of follow-up, but it did find a clinically meaningful increase in polycythemia (hematocrit rising above the safety threshold) in the testosterone group (findings attributed to the TRAVERSE trial, though the specific figures should be verified against the primary publication). If hematocrit exceeds roughly 54%, the usual response is to reduce the dose, switch formulations, or perform therapeutic phlebotomy.

PSA is typically checked at baseline, at 3 to 6 months, at 12 months, and annually thereafter, and a clinically significant PSA rise within the first year of therapy warrants urology referral. Bone density (DXA) is reasonable after one to two years of therapy in men who had osteoporosis or severe testosterone deficiency at baseline.

The Testosterone Trials (TTrials), a set of placebo-controlled trials in older men with confirmed low testosterone, reported improvements in sexual function and mood but not in vitality or cognitive function with TRT. This distinction matters for counseling: TRT is not a general energy or cognition treatment, and patients expecting across-the-board improvement should be told which domains the trial evidence actually supports.

Fourth line: adjunctive and combination therapies

Some men on TRT develop side effects or an incomplete response that prompts an add-on medication.

Aromatase inhibitors such as anastrozole are sometimes considered for symptomatic estradiol elevation (gynecomastia, nipple tenderness, fluid retention) on TRT. This is not a routine, guideline-endorsed co-prescription, and there is some evidence that aromatase inhibition in hypogonadal men may adversely affect bone mineral density over time, which argues for caution and short-term rather than indefinite use (based on limited observational data; verification of the specific effect size is recommended before quoting a precise figure).

Low-dose hCG is sometimes co-prescribed with TRT specifically to maintain intratesticular testosterone and some spermatogenic capacity. This combination is common in reproductive urology practice but is not supported by large randomized trials, so it should be framed as site judgment rather than a guideline recommendation.

Pulsatile GnRH pump therapy is reserved for secondary hypogonadism from hypothalamic disease when fertility induction is the goal and clomiphene has failed. It is a specialist-managed therapy, not something initiated in primary care.

Special populations: obesity and type 2 diabetes

Hypogonadism and metabolic disease overlap substantially. A meaningful minority of men with type 2 diabetes have biochemically low testosterone, and the American Diabetes Association's Standards of Care has addressed testing men with type 2 diabetes who have symptoms suggestive of hypogonadism, particularly low libido and erectile dysfunction (ADA Standards of Care; confirm current-year recommendation wording before quoting, since Standards of Care are revised annually). This is a targeted recommendation for symptomatic men, not a universal screening mandate for all men with diabetes.

A practical decision point clinicians use: in a man with obesity, type 2 diabetes, and a borderline-low testosterone level, a weight-loss intervention (lifestyle change, GLP-1 receptor agonist, or bariatric surgery) is a reasonable first step before committing to lifelong TRT, because functional hypogonadism from obesity can improve or resolve with sustained weight loss. Whether this is the right choice for a specific patient depends on the degree of testosterone deficiency, symptom severity, and how quickly the patient needs symptom relief.

When to refer

Referral to endocrinology is reasonable when LH and FSH are suppressed without an obvious explanation (raising concern for a pituitary mass), when prolactin is markedly elevated, when testosterone is very low with an ambiguous classification, or when a genetic cause such as Klinefelter syndrome is suspected. Urology referral is appropriate for fertility management, PSA abnormalities, or testicular pathology. Persistent hematocrit elevation above the safety threshold despite dose adjustment warrants hematology evaluation to rule out a primary blood disorder rather than assuming it is TRT-related.

Decision framework: which line of therapy fits this patient

Use this as a discussion structure with a clinician, not a self-diagnosis tool.

What is established, what is plausible, and what is not established

Established: the two-sample morning testosterone diagnostic approach, the fact that exogenous testosterone suppresses spermatogenesis, the importance of hematocrit and PSA monitoring during TRT, and the finding from the largest cardiovascular safety trial to date that testosterone gel did not show a clear cardiovascular signal versus placebo while polycythemia risk was increased.

Plausible but not fully settled: the precise magnitude of testosterone recovery from a given amount of weight loss, the comparative effectiveness of clomiphene versus hCG versus enclomiphene head-to-head, and whether nasal testosterone's pulsatile profile provides a meaningful clinical advantage over other formulations beyond avoiding transference.

Not established from the material reviewed here: routine co-prescription of aromatase inhibitors with TRT, long-term fertility outcomes with combined hCG-plus-TRT regimens, and any claim that TRT improves general vitality or cognition, which the largest dedicated trial in older men did not find.